跳转至内容
Merck

Y0000027

Sumatriptan for system suitability

European Pharmacopoeia (EP) Reference Standard

别名:

Sumatriptan succinate, 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide succinate, GR-43175

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C14H21N3O2S · C4H6O4
分子量:
413.49
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

sumatriptan

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

−20°C

SMILES 字串

OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1

InChI

1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

InChI 密鑰

PORMUFZNYQJOEI-UHFFFAOYSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Sumatriptan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Sumatriptan succinate is a 5-HT1 serotonin receptor agonist.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Warning

危險聲明

危險分類

Aquatic Chronic 3 - Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Yasunari Sakamoto et al.
World journal of gastroenterology, 18(26), 3415-3419 (2012-07-19)
To determine the effect of oral sumatriptan on gastric emptying using a continuous ¹³C breath test (BreathID system). Ten healthy male volunteers participated in this randomized, 2-way crossover study. The subjects fasted overnight and were randomly assigned to receive a
Luigi Alberto Pini et al.
The journal of headache and pain, 13(8), 669-675 (2012-10-12)
In this study, we compared the efficacy and tolerability of the combination of paracetamol 1,000 mg + caffeine 130 mg (PCF) with sumatriptan 50 mg (SUM) in migraine attacks. This was a multi-center randomized double-blind, double-dummy, cross-over controlled trial. The
Y Sekino et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 24(12), 1083-e564-1083-e564 (2012-08-14)
Oral sumatriptan administration has been reported to delay gastric emptying after liquid meals. The aim of this study was to determine whether delayed gastric emptying is caused by enhanced gastric accommodation, impaired antral contractions, or both using ultrasonography. Ten healthy
Shree G Sharma et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(2), 326-329 (2012-12-05)
Renal cortical infarction is a rare cause of acute kidney injury that results from inadequate blood flow to the kidney, most commonly as a consequence of thrombotic or embolic occlusion of the renal artery or profound hypoperfusion. We report the
M J Cózar-Bernal et al.
Journal of pharmaceutical and biomedical analysis, 72, 251-260 (2012-10-16)
In this paper, a novel, precise, specific, accurate and rapid reversed-phase high performance liquid chromatographic method was developed, optimized and validated for determining sumatriptan succinate in niosomes with the best chromatographic peak resolution, reduced run time and low cost of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门